Pluvicto Radioligand Therapy Receives Dual NMPA Approvals in China
Novartis (NYSE: NVS) has announced that its Lutetium‑177‑labelled therapy Pluvicto (lutetium ¹⁷⁷Lu‑vipivotide tetraxetan) now holds...
Sichuan Biokin Secures Breakthrough Therapy Designation for HER2‑Targeted ADC T‑Bren
China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody‑drug conjugate (ADC)...
Shenzhen Kangtai Biological Products Launches Phase I Trial for Infant Influenza Vaccine
China‑based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with...
4D Molecular Transfers Asia‑Pacific Gene‑Therapy Rights to Otsuka for $85 M Cash
4D Molecular Therapeutics (4DMT) sold the Asia‑Pacific rights to its eye‑gene therapy 4D‑150 to Otsuka...
Novo Nordisk Reports 15 % YoY Sales Growth, Cuts Full‑Year Guidance
Denmark‑based biopharma Novo Nordisk A/S (NYSE: NVO) disclosed Q1‑Q3 2025 financials that show a 15 %...
China CDE Opens Public Comment on 100th Batch of Reference Standards for Chemical Generic Drugs
The China Center for Drug Evaluation (CDE) has released a draft list of the 100th...
MSD Secures Full Global Rights to MK‑8690 After $150 Million Settlement with Falk Pharma
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences,...
China’s National Health Commission Launches “Silver‑Haired” Healthcare & Elderly‑Care Initiative
The National Health Commission (NHC) has issued a formal notice to roll out the Silver‑Haired...
China’s National Health Commission Issues “AI + Healthcare” Implementation Opinions – Roadmap for 24 Standardized Applications
The National Health Commission (NHC) today released the Implementation Opinions on Promoting and Standardizing the...
Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China
Zhejiang Acea Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...
Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China
Daiichi Sankyo Co., Ltd. (TYO: 4568) announced that China’s Center for Drug Evaluation (CDE) of...
Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal
Biotech‑focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a “superior” acquisition...
Roche Announces a $55 M Partnership with Manifold Bio to Build BBB Shuttles
Swiss‑listed pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) confirmed a strategic alliance with platform biotech...
Eli Lilly Announces Phase 3 ATTAIN‑PAD Trial for Oral GLP‑1 Agent orforglipron
Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN‑PAD phase 3 study—an ambitious,...
Green Valley Faces Bribery Fine as Re‑registration Deadline Passes
The Shanghai Pudong New Area Market Supervision Administration issued an administrative penalty against Green Valley...
CARsgen Therapeutics Shares Promising Early Results for Allogeneic CAR‑T Products
China‑based CARsgen Therapeutics Holdings Limited (HKG: 2171) unveiled clinical data for two allogeneic CAR‑T candidates...
Guangzhou’s 12‑Step Plan to Accelerate Innovative Drug and Device Adoption
The Guangzhou Municipal Health Commission issued a comprehensive notice detailing twelve strategic measures aimed at...
Hengrui Gets NMPA Green Light for Rezvilutamide‑HS‑20093 Combination Trial in Prostate Cancer
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the China...
CStone Receives NMPA Approval for CS2009 Phase II Trial in Advanced Solid Tumors
China‑based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA)...
NHSA Re‑designs Drug‑Prescribing Surveillance, Targeting Illicit Use and Resale
The National Healthcare Security Administration issued a comprehensive notice to strengthen the intelligent monitoring of...